BC Platforms partners with European Genomics Service Provider Center Life & Brain for SNP genotyping and analysis market
The
growing incidence and prevalence of genetic disorders are supporting the growth
of the global SNP genotyping and analysis market. For instance, according to
the Summary of the Cystic Fibrosis Foundation Patient Registry, 2003–2018, the
number of people with cystic fibrosis increased from 21,421 in 2003 to 30,775
in 2018. Increasing adoption of a strategic alliance among key players is again
fostering the growth of the SNP genotyping and analysis market. For instance,
in April 2020, Indivumed GmbH, an oncology company, launched the Oncology
Alliance for Individualized Medicine, an international collaborative alliance
to advance personalized medicine in cancer through IndivuType, the company’s
multi-omics database. Growing technological advancement is another key factor
fostering the growth of the market.
The
field of SNP or Single Nucleation Polymorphism genomics is a method to study
and profile the genetic differences of SNPs along with testing individuals
against a reference panel of genetic variants. It is still in its early days of
development and research but has already produced many important advances over
the last decade. SNP genomics has proven to be an effective way to study the
human genome by identifying individual genetic differences that may affect
disease states or traits. These tests are currently being used in a number of
different settings, including clinical genomics, experimental genetics, and
public health. As time goes on we will undoubtedly see even more progress made
using this method of genetic analysis.
Major
players operating in the global SNP genotyping and analysis market include LGC
Limited, Fluidigm Corporation, Illumina, Inc., Life Technologies Corporation,
PREMIER Biosoft, Thermo Fisher Scientific, and Sequenom, Inc.
North
America is expected to dominate the global SNP
genotyping and analysis market and this is attributed to the high
prevalence of genetic disorder in the region which is creating demand for
genotyping. According to the National Institutes of Health, about 1 in 200,000
people in the United States are diagnosed with syndrome A each year. An
estimated 15,000 people worldwide were diagnosed with syndrome B last year.
Key Developments:
1. In July 2019, Thermo Fisher Scientific launched
three new Applied Biosystems AgriSeq targeted genotyping by sequencing
solutions that will allow customers to genotype canines and felines.
2. In April 2020, Researchers from Jung P & C
Institute, Inc., South Korea, used Bayesian methods under different genotyping
platforms to perform genomic analysis in Korean Duroc pigs.
3. In December 2019, BC Platforms partners with
European Genomics Service Provider Center Life & Brain to expand genotyping
services across Europe
Comments
Post a Comment